NovaBridge Biosciences (NBP) Total Current Liabilities (2018 - 2026)

NovaBridge Biosciences (NBP) has reported Total Current Liabilities for 8 consecutive years, with $26.9 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Total Current Liabilities rose 218.12% year-over-year to $26.9 million; the TTM figure through Dec 2025 stood at $26.9 million (up 218.12% YoY), while the FY2025 annual figure was $26.9 million, up 218.12% from the prior year.
• Total Current Liabilities climbed to $26.9 million in Q4 2025 per NBP's latest filing, from $16.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $97.6 billion in Q4 2021 and bottomed at $2.0 million in Q2 2024.
• Historically, Total Current Liabilities has averaged $7.5 billion across 5 years, with a median of $26.9 million in 2025.
• Annual changes were most pronounced in 2021 — Total Current Liabilities soared 112170.09% — and 2022, when it plunged 99.89%.
• NovaBridge Biosciences' Total Current Liabilities stood at $97.6 billion in 2021, then slumped by 99.89% to $106.6 million in 2022, then plunged by 46.35% to $57.2 million in 2023, then tumbled by 85.22% to $8.5 million in 2024, then jumped by 218.12% to $26.9 million in 2025.
• Business Quant data shows NBP's Total Current Liabilities at $26.9 million in Q4 2025, $16.1 million in Q3 2025, and $7.3 million in Q2 2025.